secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0001104659-25-030839
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise reports positive Phase 2 data for EDG-7500 in HCM; 71% LVOT-G reduction at rest
--------------------------------------------------------------------------------

- Obstructive HCM: 100 mg dose achieved mean 71% reduction in resting LVOT-G and 58% in provokable gradients over 4 weeks.
- NT-proBNP reduced 62% in obstructive and 42% in nonobstructive HCM at 100 mg; KCCQ-OSS improved 23 and 17 points respectively.
- No LVEF <50%; two participants had serious AF requiring cardioversion; one discontinuation due to dizziness.
- Part D 12-week data expected H2 2025; Phase 3 CIRRUS-HCM trial initiation planned for H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/0001104659-25-030839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925030839/tm2510984d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-030839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer